It is now accepted as an established truth among payers that new drugs approved by US Food & Drug Administration in recent years have less efficacy evidence than used to be expected.
During one recent industry conference hosted by a leading specialty pharmacy company, that assertion was made repeatedly as one of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?